Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Breast Neoplasms 3Melanoma 2Carcinoma, Renal Cell 2Carcinoma 2Skin Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Lung Neoplasms 1

Interventions

10-propargyl-10-deazaaminopterin 6Brentuximab Vedotin 5romidepsin 3Vitamin B 12 3Rituximab 3Folic Acid 3Cyclophosphamide 3tenalisib 2cobomarsen 2belinostat 2Vincristine 2Prednisone 2Gemcitabine 2Doxorubicin 2zanubrutinib 1zanolimumab 1venetoclax 1tislelizumab 1quisinostat 1pembrolizumab 1mogamulizumab 1fostamatinib 1forodesine 1fludarabine 1enzastaurin 1enzalutamide 1duvelisib 1denileukin diftitox 1darinaparsin 1cc-486 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, T-Cell × ProMune × Clear all
NCT00043368 2009-03-12

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

Pfizer

Phase 2 Completed
31 enrolled
BreastDermatologicGenitourinaryLymphoidThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡